Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

M Colombo1

  • 1Institute of Internal Medicine, University of Milan and IRCCS, Ospedale Maggiore, Milan, Italy.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Optimizing interferon-alpha therapy for chronic hepatitis C involves considering patient factors like age and viral genotype. Prospective validation of these predictors is crucial for effective clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Italian Club of Osteosynthesis (CIO): Current Trends in Orthopaedic Trauma Care.

Injury·2024
Same author

EVALUATION OF PREDICTORS OF INEFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN THE REPUBLIC OF KAZAKHSTAN: A MATCHED CASE-CONTROL STUDY.

Georgian medical news·2024
Same author

Motor and Cognitive Modulation of a Single Session of Transcutaneous Auricular Vagus Nerve Stimulation in Post Stroke Patients: A Pilot Study.

IEEE open journal of engineering in medicine and biology·2024
Same author

PerBrain: a multimodal approach to personalized tracking of evolving state-of-consciousness in brain-injured patients: protocol of an international, multicentric, observational study.

BMC neurology·2022
Same author

Direct quantification of cytosolic delivery of drug nanocarriers using FlAsH-EDT2.

Nanomedicine : nanotechnology, biology, and medicine·2022
Same author

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells.

Nanoscale advances·2022
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Pharmacotherapy

Background:

  • Interferon-alpha therapy is a key treatment for chronic hepatitis C.
  • Increasing dosage and duration may improve outcomes but presents tolerability and cost issues.
  • Refining treatment indications based on outcome predictors offers an alternative optimization strategy.

Purpose of the Study:

  • To evaluate patient-specific factors as predictors of treatment response in chronic hepatitis C.
  • To assess the potential of pretreatment variables for optimizing interferon-alpha therapy.
  • To determine the necessity of prospective validation for clinical application of predictive factors.

Main Methods:

  • Analysis of patient demographics, disease characteristics, and viral factors.

Related Experiment Videos

  • Statistical evaluation of pretreatment viraemia, viral genotype, patient age, disease duration, and severity.
  • Assessment of the predictive power and independence of identified variables.

    • Main Results:

    • Patient age, disease duration, disease severity, pretreatment viraemia, and viral genotype are associated with interferon-alpha treatment response.
    • These variables exhibit varying statistical power and predictive independence.
    • The predictive utility requires prospective validation before clinical implementation.

    Conclusions:

    • Predictive factors for interferon-alpha therapy in chronic hepatitis C exist.
    • Careful selection of patients based on these predictors can optimize treatment.
    • Prospective studies are essential to confirm the clinical utility of these predictive markers.